CSS
CRSP icon

Cubist Systematic Strategies’s CRISPR Therapeutics CRSP Stock Holding History

Cubist Systematic Strategies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,195
Closed -$2.08M – 3816
2023
Q4 		$2.08M Buy
+33,195
New +$1.84M 0.01% 1478
2023
Q2 		– Sell
-10,736
Closed -$609K – 3635
2023
Q1 		$486K Sell
10,736
-157,691
-94% -$7.66M ﹤0.01% 2682
2022
Q4 		$6.85M Buy
168,427
+158,738
+1,638% +$8.42M 0.04% 764
2022
Q3 		$633K Sell
9,689
-30,803
-76% -$2.23M ﹤0.01% 2989
2022
Q2 		$2.46M Buy
40,492
+9,441
+30% +$555K 0.02% 1656
2022
Q1 		$1.95M Buy
31,051
+1,265
+4% +$79.4K 0.02% 1499
2021
Q4 		$2.26M Buy
29,786
+23,689
+389% +$2.07M 0.02% 1255
2021
Q3 		$682K Sell
6,097
-7,330
-55% -$921K 0.01% 1813
2021
Q2 		$2.17M Buy
13,427
+9,367
+231% +$1.14M 0.02% 1027
2021
Q1 		$495K Sell
4,060
-44,278
-92% -$6.69M 0.01% 1966
2020
Q4 		$7.4M Buy
48,338
+7,301
+18% +$863K 0.1% 263
2020
Q3 		$3.43M Buy
41,037
+28,777
+235% +$2.55M 0.05% 589
2020
Q2 		$901K Sell
12,260
-1,310
-10% -$76.6K 0.02% 1242
2020
Q1 		$576K Sell
13,570
-33,570
-71% -$1.73M 0.02% 1165
2019
Q4 		$2.87M Buy
47,140
+41,040
+673% +$2.24M 0.05% 556
2019
Q3 		$250K Sell
6,100
-1,050
-15% -$50.2K 0.01% 1650
2019
Q2 		$337K Buy
7,150
+4,767
+200% +$191K 0.01% 1719
2019
Q1 		$85K Sell
2,383
-37,167
-94% -$1.29M ﹤0.01% 2026
2018
Q4 		$1.13M Buy
39,550
+34,465
+678% +$1.2M 0.05% 506
2018
Q3 		$226K Buy
+5,085
New +$266K 0.01% 1350

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Cubist Systematic Strategies's CRSP Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 33,195 shares — an estimated $2.08M sold.

Cubist Systematic Strategies first reported a position in CRSP in Q3 2018 and held it in 20 quarters. The position peaked at $7.4M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 33,195 CRISPR Therapeutics shares in Q1 2024, an estimated $2.08M.
  • Cubist Systematic Strategies first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 20 quarters.
  • Cubist Systematic Strategies's CRISPR Therapeutics position peaked at $7.4M in Q4 2020.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.